| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Camptothecin (CPT) and its derivatives function as inhibitors of topoisomerase and as potent anticancer agents against a variety of cancers. Camptothecin is a cytotoxic quinoline alkaloid that is isolated from the bark and fruit of the Camptotheca acuminata tree, native to China. It is a topoisomerase I inhibitor, which means it blocks the enzyme topoisomerase I, an essential enzyme in DNA replication. Camptothecin derivatives, such as irinotecan and topotecan, have been approved for the treatment of various types of cancer, including colorectal, ovarian, and small cell lung cancer. These derivatives have improved solubility and stability compared to camptothecin, making them more suitable for clinical use. Camptothecin — Camptothecin (CPT) is a naturally occurring pentacyclic quinoline alkaloid and canonical topoisomerase I poison originally isolated from Camptotheca acuminata. It is classified as a plant-derived cytotoxic small-molecule antineoplastic scaffold. Standard abbreviations include CPT and 20(S)-camptothecin. The parent compound is historically important because it established the camptothecin/topoisomerase I inhibitor class, but the parent drug itself has not become a standard approved systemic anticancer drug because of poor aqueous solubility, rapid loss of the active lactone under physiologic conditions, and major toxicity; instead, clinically successful descendants include topotecan and irinotecan. Primary mechanisms (ranked):
Bioavailability / PK relevance: PK is a major translation constraint. The active closed lactone is favored in acidic conditions but rapidly hydrolyzes at physiologic pH toward the less active carboxylate; albumin binding further shifts equilibrium toward the carboxylate. Parent CPT is also poorly water-soluble, which contributed to failed early development of the parent molecule and motivated semisynthetic analogs, prodrugs, and nanoparticle formulations. In-vitro vs systemic exposure relevance: For the parent compound, many in-vitro studies demonstrate mechanism cleanly, but direct systemic use is limited by formulation instability and toxicity rather than lack of target engagement. Thus, in-vitro potency often overstates practical exposure feasibility for parent CPT; clinically relevant translation usually depends on derivatives or delivery systems rather than free CPT itself. Clinical evidence status: Parent camptothecin: preclinical / historical early clinical experience with poor therapeutic index and no standard approval. Camptothecin class derivatives: strong human evidence and regulatory deployment through approved agents such as topotecan and irinotecan. Modern work on parent-CPT formulations remains investigational and largely delivery-driven. Camptothecin mechanistic table
TSF: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| Cytochrome c ** The term "release of cytochrome c" ** an increase in level for the cytosol. Small hemeprotein found loosely associated with the inner membrane of the mitochondrion where it plays a critical role in cellular respiration. Cytochrome c is highly water-soluble, unlike other cytochromes. It is capable of undergoing oxidation and reduction as its iron atom converts between the ferrous and ferric forms, but does not bind oxygen. It also plays a major role in cell apoptosis. The term "release of cytochrome c" refers to a critical step in the process of programmed cell death, also known as apoptosis. In its new location—the cytosol—cytochrome c participates in the apoptotic signaling pathway by helping to form the apoptosome, which activates caspases that execute cell death. Cytochrome c is a small protein normally located in the mitochondrial intermembrane space. Its primary role in healthy cells is to participate in the electron transport chain, a process that helps produce energy (ATP) through oxidative phosphorylation. Mitochondrial outer membrane permeability leads to the release of cytochrome c from the mitochondria into the cytosol. The release of cytochrome c is a pivotal event in apoptosis where cytochrome c moves from the mitochondria to the cytosol, initiating a chain reaction that leads to programmed cell death. On the one hand, cytochrome c can promote cancer cell survival and proliferation by regulating the activity of various signaling pathways, such as the PI3K/AKT pathway. This can lead to increased cell growth and resistance to apoptosis, which are hallmarks of cancer. On the other hand, cytochrome c can also induce apoptosis in cancer cells by interacting with other proteins, such as Apaf-1 and caspase-9. This can lead to the activation of the intrinsic apoptotic pathway, which can result in the death of cancer cells. Overexpressed in Breast, Lung, Colon, and Prostrate. Underexpressed in Ovarian, and Pancreatic. |
| 324- | AgNPs, | CPT, | Silver Nanoparticles Potentiates Cytotoxicity and Apoptotic Potential of Camptothecin in Human Cervical Cancer Cells |
| - | in-vitro, | Cerv, | HeLa |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:204 Target#:77 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid